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Highlights 
 Systemic administration of nitroglycerin and anandamide are able to increase the 
expression of serotonin transporter at the level of caudal trigeminal nucleus 
 The combined nitroglycerin and anandamide treatment attenuated this effect 
 A complex interaction might be present between the serotoninergic, nitrergic and the 
endocannabinoid system 
 
Abstract 
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Migraine is one of the most prevalent neurological diseases, which affects 16% of the total 
population. The exact pathomechanism of this disorder is still not well understood, but it 
seems that serotonin and its transporter has a crucial role in the pathogenesis.  
One of the animal models of migraine is the systemic administration of nitroglycerin (NTG), 
a nitric oxide (NO) donor. NO can initiate a central sensitization process in the trigeminal 
system, which is also present in migraineurs. 
Recent studies showed that the endocannabinoid system has a modulatory role on the 
trigeminal activation and sensitization.  
Our aim was to investigate the effect of an endogenous cannabinoid, anandamide (AEA) on 
the NTG-induced changes on serotonin transporter (5-HTT) expression in the upper cervical 
spinal cord (C1-C2) of the rat, where most of the trigeminal nociceptive afferents convey. 
The animals were divided into four groups. Rats in the first group, called placebo, received 
only the vehicle solution as treatment. In the second group, they were treated with an 
intraperitoneal (i.p.) injection of NTG (10mg/kg). Rats in the third and fourth groups received 
i.p. AEA (2x5mg/kg) half hour before and one hour after the placebo or NTG treatment. Four 
hours after placebo/NTG injection, the animals were perfused and the cervical spinal cords 
were removed for immunohistochemistry and Western blotting. 
Our results show that both NTG and AEA alone are able to increase 5-HTT expression in the 
C1-C2 segments. Combination of NTG and AEA has an opposing effect on this marker, 
nullifying the effects of non-combined administration, probably by negative feedback 
mechanisms.  
 
1Abbreviations: 5-HT-serotonin, 5-HTT-serotonin transporter, AEA-anandamide, C1-C2-
upper cervical spinal cord, CSD-cortical spreading depression, GAPDH-glyceraldehyde 3, 
phosphate dehydrogenase, intraperitoneal-i.p., nNOS-neuronal nitric oxide synthase, NO-
nitric oxide, NTG-nitroglycerin, PBS-phosphate-buffered saline, TBST-Tris-buffered saline 
containing Tween 20 
 
Key words: migraine, trigeminal system, nitroglycerin, anandamide, serotonin, serotonin 
transporter 
 
1. Introduction 
Migraine is a chronic neurological disorder characterized by recurrent headaches lasting for 4-
72 hours and commonly accompanied by nausea, photophobia and phonophobia. This 
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syndrome affects 16% of the total population (Smitherman et al., 2013). The exact 
pathomechanism of the disease is not fully known, but it has been suggested that serotonin or 
5-hydroxytryptamine (5-HT) has an important role in the migraine attack (Ferrari and Saxena, 
1993). In 1961, Sicuteri and colleagues have shown that the excretion in the urine of 5-
hydroxyindoleacetic acid, the principal catabolite of 5-HT, was increased during some attacks 
of migraine headache (Sicuteri, 1961) and these findings were verified by Curran and co-
workers in 1965 (Curran et al., 1965). Despite these data, the exact role of 5-HT in the 
pathogenesis of migraine is not fully clear.  
Serotonin transporter (5-HTT) removes 5-HT from the synaptic cleft back into the pre-
synaptic terminals, mitigating the effect of 5-HT. In patients with familial hemiplegic 
migraine, Horvath and colleagues have found low 5-HT levels in the platelets, reduced 5-HT 
transport capacity and low metabolite levels in the cerebrospinal fluid (Horvath et al., 2011). 
In a neuroimaging study increased 5-HTT availability in the mesopontine brainstem of 
migraineurs has been detected (Schuh-Hofer et al., 2007).  Data show that the vast majority of 
5-HTT is localized on the axolemma, in the vicinity of the synapses, and along the axons as 
well. This distribution suggests that the transporter may play a role not only in the termination 
of synaptic transmission, but in the general extracellular 5-HT regulation. Intracellularly, it 
has been demonstrated in low amount in the soma and dendrites (Tao-Cheng and Zhou, 1999; 
Zhou et al., 1998). Depending on the stimulus, 5-HT uptake and 5-HTT trafficking may be 
differentially affected, but are often linked with altered 5-HTT basal phosphorylation by 
Ser/Thr protein kinases (Annamalai et al., 2012; Ramamoorthy et al., 1998). 
Nitroglycerin (NTG)-administration is a model of migraine, being able to generate migraine 
attacks in migraineurs (Sicuteri et al., 1987), and trigger activation and sensitization in the 
trigeminal system (Di Clemente et al., 2009). It is also well-known, that NTG-a nitric oxide 
donor (NO)-can initiate trigeminal activation and sensitization in animals as well (Pardutz et 
al., 2000; Tassorelli and Joseph, 1995). In rats, it has been shown that NTG produced an 
increase in the area covered by 5-HT-immunoreactive fibres (Pardutz et al., 2002), which 
suggests that NO influences the 5-HT system.  
Cannabis has been sporadically used to reduce nausea and vomiting during chemotherapy and 
to treat pain, migraine and muscle spasticity (Borgelt et al., 2013). The interactions between 
the endocannabinoid system and pain perception are intensively studied in several 
laboratories, but the psychoactive properties of cannabinoids (Crawley et al., 1993) restrict 
their therapeutic application. On the other hand, a recent retrospective study shows, that 
medical marijuana is able to decrease the frequency of migraine attacks (Rhyne et al., 2016). 
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The alteration of platelet 5-HT homeostasis was considered to be connected with the 
pathogenesis of migraine headache (Danese et al., 2014). Research data show a strong 
interaction between the cannabinoid and 5-HT system in platelets: ∆1-tetrahydrocannabinol 
blocked 5-HT release from the thrombocytes (Volfe et al., 1985), whereas platelet 5-HT 
uptake was inhibited by various cannabinoids (Velenovska and Fisar, 2007; Volfe et al., 
1985). The interaction of cannabinoid and 5-HT systems at the periphery is well documented, 
but for the better understanding of migraine pathophysiology experimental data are needed 
about such possible mechanism in the CNS. 
Anandamide (AEA) is an extensively studied endocannabinoid, which is effective in the 
inhibition of trigeminal activation and central sensitization in animals (Greco et al., 2010a; 
Nagy-Grocz et al., 2015). AEA is an agonist of both cannabinoid 1 and 2 receptors and the 
transient receptor potential vanilloid type 1 receptor.  
The goal of the present study was to investigate the effect of NTG and AEA on the 5-HTT 
expression levels, in one of the central nervous system structures relevant in migraine: the 
superficial laminae of the upper cervical spinal cord (C1-C2) with immunohistochemistry and 
Western blotting.  
 
2. Materials and methods 
2.1. Animals: 
The procedures utilized in this study followed the guidelines for the Use of Animals in 
Research of the International Association for the Study of Pain and the directive of the 
European Economic Community (86/609/ECC). They were permitted by the Committee of 
the Animal Research of University of Szeged (I-74-12/2012) and the Scientific Ethics 
Committee for Animal Research of the Protection of Animals Advisory Board 
(XI./352/2012). Forty-four adult male Sprague-Dawley rats weighing 200-250 grams were 
used. The animals were raised and maintained under standard laboratory conditions, with tap 
water and regular rat chow available ad libitium on a 12 hour dark-12 hour light cycle. 
2.2. Drug administration: 
The animals were divided into four groups (n=6 per group in the immunohistochemistry, n=5 
in the Western blot). The animals in the first (placebo) group, received only the vehicle 
solution as pretreatment. In the second group, the rats were pretreated with an intraperitoneal 
(i.p.) injection of NTG (10 mg/kg bodyweight, Pohl Boskamp). In the third and fourth groups, 
rats were given AEA (2x5 mg/kg) injection half hour before and one hour after the placebo or 
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NTG treatment. AEA was dissolved in physiological saline. In the first and second groups, 
animals were treated with physiological saline instead of AEA.  
2. 3. Immunohistochemistry: 
Four hours after the placebo/NTG injection, the rats were perfused transcardially with 100 ml 
phosphate-buffered saline (PBS, 0.1 M, pH 7.4), followed by 500 ml 4% paraformaldehyde in 
phosphate-buffer in chloral hydrate (0.4 g/kg bodyweight) anesthesia. The C1-C2 segments of 
the cervical spinal cord between -5 and -11 mm from the obex, which receive important 
nociceptive information from the head (Strassman et al., 1993) were removed and postfixed 
overnight for immunohistochemistry in the same fixative. After cryoprotection, 30 μm 
cryostat sections were cut and serially collected from C1-C2 in wells containing cold PBS. 
The free-floating sections were rinsed in PBS and immersed in 0.3% H2O2 in or PBS for 30 
minutes. After several rinses in PBS containing 1% Triton X-100, sections of C1-C2 were 
kept for two nights at 4 °C in anti-5-HTT antibody (Merck Millipore, ab9726) at a dilution of 
1:100 000. The immunocytochemical reaction was visualized by the avidin-biotin kit of 
Vectastain (PK6101), and nickel ammonium sulphate -intensified 3,3’-diaminobenzidine. The 
specificity of the immune reaction was controlled by omitting the primary antiserum. 
 
2.4. Western blot analysis:  
Four hours after the placebo/NTG injection, the animals were perfused transcardially with 
100 ml PBS then the dorsal horns of C1-C2 segments were extracted. Until the measurements, 
the samples were stored −80 °C. The specimens were sonicated in ice cold lysis buffer 
containing 50 mM Tris-HCl, 150 mM NaCl, 0.1% igepal, 0.1% cholic acid, 2 μg/ml 
leupeptin, 2 mM phenylmethylsulphonyl fluoride, 1 μg/ml pepstatin, 2 mM EDTA and 0.1% 
sodium dodecyl sulphate. The lysates were centrifuged at 12,000 RPM for 10 minutes at 4 °C 
and supernatants were aliquoted and stored at -20 °C until use. Protein concentration was 
defined with BCA Protein Assay Kit using bovine serum albumin as a standard. Previous to 
loading, each sample was mixed with sample buffer, and denaturated by boiling for 3 
minutes. Equal amounts of protein samples (20 μg/lane) were separated by standard SDS 
polyacrylamide gel electrophoresis on 10% Tris–Glycine gel and electrotransferred onto 
Amersham Hybond-ECL nitrocellulose membrane (0.45 μm pore size, GE Healthcare). We 
used The Page Ruler Prestained Protein Ladder (Thermo Scientific, 10-170 kDa) to define 
approximate molecular weights. Following the transfer, membranes were blocked for one 
hour at room temperature in Tris-buffered saline containing Tween 20 (TBST) and 5% non fat 
dry milk. Then they were incubated in TBST containing 1% non fat dry milk and 5-HTT 
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antibody (Merck Millipore, ab9726, dilution: 1:2000, incubation: overnight at 4 °C) or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Cell Signaling 
Technologies, 8884, dilution: 1:1000, incubation: overnight at room temperature). Next day, 
membranes were incubated in TBST containing 1% non fat dry milk and horseradish 
peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology; sc-2030) 
for two hours at room temperature. Protein bands were visualized after incubation of 
membranes with the SuperSignal West Pico Chemiluminescent Substrate using Carestream 
Kodak BioMax Light film. 
 
2.5. Data evaluation:  
All evaluations were implemented by an observer blind to the experimental groups. The 
detailed methods were described previously (Nagy-Grocz et al., 2015).  
Immunohistochemistry: 
The photomicrographs of the stained sections of C1-C2 were taken using Zeiss AxioImager 
microscope supplied with an AxioCam MRc Rev.3 camera (Carl Zeiss Microscopy, Jena, 
Germany). The density of the 5-HTT-immunoreactive fibres was analyzed by Image Pro Plus 
6.2® software (Media Cybernetics). After capturing the images, the borders of laminae I, II 
and III of the dorsal horn were defined manually as areas of interest (AOI). The background 
level of the staining intensity was first determined in the recorded gray scale images, which 
was used as a threshold to segment pixels in the AOI with grey levels above the background, 
as described in details earlier (Nagy-Grocz et al., 2015). The area innervated by the 
immunoreactive fibres was expressed as the cumulative number of pixels with densities above 
the threshold. Finally, the relative area covered by immunoreactive fibres and in the different 
laminae was calculated as area fractions (%) of the appropriate AOI. To exclude possible 
errors originating from different staining efficiency in separate experiments, background 
intensities in indifferent areas on the sections with non-specific staining were measured and 
used as inter-experimental controls. 
Higher magnification photos were also taken to determine the sizes of immunoreactive 
varicosities by the same digital system using 40x objective. For the determination of the 
cross-sectional areas we selected processes which were in focus and were recognized and 
measured by the program as single objects.  Measurements were carried out as above.   
Western blot analysis: 
For densitometric analyses, films were scanned and quantified using Java ImageJ 1.47v 
analysis software (National Institutes of Health). GAPDH served as a control to ensure 
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loading of equivalent amounts of sample proteins and measured protein levels of 5-HTT were 
normalized to GAPDH. 
2.6. Statistical analysis: 
Statistical analysis of measurements were performed in SPSS Statistics software (Version 
20.0 for Windows, SPSS Inc.) by one-way analysis of variance followed by the Fishers Least 
Significant Difference post hoc test, with p<0.05 taken as statistically significant. Normality 
was tested with Shapiro-Wilk test. Group values are reported as means ± S.E.M. 
 
3. Results 
NTG and AEA raise 5-HTT expression in the C1-C2, but the combined treatment inhibits this 
effect-Immunohistochemistry data 
 
On microscopic investigation (20x objective) of transverse sections of the C1-C2 segments, 
there were abundant 5-HTT-positive fibres in the superficial layers (I-III) of the dorsal horn. 
In animals sacrificed four hours after i.p. NTG-injection the 5-HTT-immunoreactive area was 
significantly higher in each layers compared to the placebo-treated group (p<0.01). This effect 
has been experienced also in the AEA-treated animals (p<0.01; p<0.001). It is interesting that, 
in the combined NTG+AEA treated group the 5-HTT area fractions were significantly 
decreased (p<0.01) as compared either with the NTG or the AEA treated groups (lamina I: 
F(3,20)=26.556; p=2x10-6; lamina II: F(3,20)=92.104; p=2.62x10-10; lamina III: 
F(3,20)=45.300; p=4,81x10-8). (Fig.1) 
 
NTG and AEA also enhance the sizes of the 5-HTT varicose fibres in the C1-C2, but the 
combined treatment reduces this effect-Immunohistochemistry data 
 
On higher magnification (40x objective), the microscopic examination of the sections 
revealed numerous immunoreactive processes. The average size of the fiber varicosity was 
significantly higher in the NTG or AEA treated animals compared to the placebo-treated 
group (p<0.05). In the combined NTG+AEA treated group, the sizes was reduced (p<0.05) as 
compared to the NTG or the AEA treated groups (F(3,20)=12.071; p=9.9x10-5) (Fig.2) 
 
NTG and AEA increase 5-HTT expression in the C1-C2, but the combined administration 
attenuates this effect-Western blot data 
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Western blot analysis of the C1-C2 region confirmed the results obtained by 5-HTT 
immunohistochemistry. The characteristic band of 5-HTT was visualized at 64 kDa. 
Densitometric analysis showed that, in the NTG and AEA treated groups 5-HTT bands were 
significantly increased (p<0.01) as compared with the placebo-treated group. After the 
combined NTG+AEA treatment the bands were significantly decreased (p<0.05; p<0.01) as 
compared either with the NTG or the AEA treated groups (F(3,16)=8.088; p=2x10-3). (Fig.3) 
 
4. Discussion 
Despite the fact that the role of 5-HT in the migraine pathogenesis is generally accepted, the 
exact molecular mechanism of its effect is far from being clearly understood. One of the key 
molecules of 5-HT signaling mechanisms is its membrane transporter 5-HTT, which is 
responsible for the cellular internalization of the released transmitter, thereby terminating its 
effect.  
In our present study, we found an increase in 5-HTT and processes expression after the NTG 
administration in rat C1-C2 segments, where most of the trigeminal nociceptive afferents 
terminate. Our western blot data demonstrate that the endocannabinoid AEA has similar 
effect; its administration increases the 5-HTT expression. 
From functional point of view the observed changes, i.e. the increased transport of 5-HT may 
indicate a decrease in the serotonergic activity in these brain areas. These observations are in 
line with previous neuroimaging and molecular biology studies. By using neuroimaging 
methods (SPECT-images coregistered with MRI-scans) (Schuh-Hofer et al., 2007) it was 
shown that there is an increased availability of 5-HTT in brainstem in migraine patients 
during the interictal period. The recent PET-study also confirms that the 5-HTT availability is 
crucial in the pathomechanisms of migraine (Park et al., 2016). The limitation of the complete 
comparison of our results with the clinical studies is that the human observations are 
examining migraine during the interictal period opposite the NTG model of migraine, which 
is the ictal model of migraine. On the other hand, clinical and experimental data from several 
laboratories clearly indicate that the 5-HTT gene is one of the genetically contributing factors 
of migraine (Murphy et al., 2001). In migraine patients with and without aura it has been 
shown an altered allelic division of the 5-HTT (Ogilvie et al., 1998). 
Our data give more emphasis on the role of the transporter in the regulation of 5-HT levels 
and provide further evidences for the crosstalk existing between serotonergic and NO systems 
(Miller and Hoffman, 1994; Zhu et al., 2004). By using proteomic methods Chanrion et al. 
showed that the 5-HTT interacts with the nNOS and they concluded that this physical 
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association may make reciprocal modulation possible (Chanrion et al., 2007). It was also 
shown that the application of L-NAME (a nonspecific nNOS inhibitor) reduces the vascular 
abnormalities which are induced by the CSD-triggered 5-HT depletion, suggesting that NO 
production has a pivotal role in the CSD caused 5-HT depletion (Saengjaroentham et al., 
2015). In addition, Harkin and co-workers showed that inhibition of NO synthase could be 
used as a strategy to raise the clinical efficacy of serotonergic antidepressants, enhancing the 
activity of the drug (Harkin et al., 2004). 
A previous study found an increase in the 5-HT-IR fibres in C1-C2 of rats in the NTG-model, 
which may indicate a reduced release of 5-HT from the terminals (Pardutz et al., 2002). Our 
present data suggests that NTG may increase 5-HT reuptake and may reduced its levels in the 
synaptic cleft. In addition, the increased 5-HTT varicosity may suggest a raised 5-HT 
turnover, as well. This data is in accordance with the HPLC results of Tassorelli and her 
group, which was shown that NTG can decrease the levels of 5-HT in rats medullary 
segments (Tassorelli et al., 2002). It has been observed, that the depletion of tryptophan 
(precursor of 5-HT) is positively correlated with the severity of the headache in migraineurs 
(Drummond, 2006), and for that reason the decreased level of 5-HT is a crucial factor in the 
trigeminal activation and the pathomechanism of migraine.  
According to our data the endocannabinoid AEA had an effect on the 5-HTT too, it increased 
its expression. Literature data show that AEA regulates the expression of several genes and 
some of its effect is receptor (CB1) dependent, but receptor independent actions have also 
been reported (Correa et al., 2008; Mestre et al., 2011; Sancho et al., 2003). One can not 
exclude the possibility of some indirect action, because it is known that endocannabinoids are 
able to raise NO production by upregulating the nNOS activity (Carney et al., 2009). It is 
therefore possible that the increase of 5-HTT expression is due to the increase of NO after the 
administration of AEA. The possible role of the endocannabinoid system in the descending 
modulation of the trigeminal complex was characterized by Akerman and his group. They 
showed that CB1 receptor activation is able to inhibit the trigeminal nociceptive pathway and 
AEA is involved in the modulation of the descending trigeminovascular nociception 
(Akerman et al., 2013; Akerman et al., 2004). In our previous study, we investigated the 
effect of AEA on the markers of sensitization and inflammation in the NTG model (Nagy-
Grocz et al., 2015). Taken together, AEA was able to inhibit the NTG induced changes, 
suggesting that AEA would have beneficial effect of migraine pathophysiology, while the 
interaction with the serotonergic axis might be more complex.  
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It was quite unexpected that in animals treated with NTG+AEA we could not detect changes 
in 5-HTT expression. The present data do not permit us to explain all aspects of this 
phenomenon, but we can not exclude the possibility of a negative feed-back mechanism, since 
both NTG and AEA increase cGMP and NO levels (Carney et al., 2009). It is also worth 
considering, that administration of NTG increases the activity of enzymes, which break down 
endogenous endocannabinoids in the midbrain of rats (Greco et al., 2010b), suggesting, that 
NTG is able to influence the endocannabinoid pathway.  
On the other hand, we do not exclude that the combined treatment may act at gene expression 
level, and the accelerated induction of 5-HTT synthesis and the rapid reversability of 
expression may result in a recovery to the control level by 4 hours. 
Further experiments are needed to reveal the molecular background of this interesting 
observation. 
 
5. Conclusion 
The present study has demonstrated that NTG and AEA alone, and in a combined treatment 
are able to modulate 5-HTT expression. These finding suggest a complex interaction between 
the serotonergic and endocannabinoid system on the NTG-induced trigeminal activation and 
sensitization phenomenon, which are important during migraine attack.  
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Figure captions 
 
Figure 1. Summary of immunohistochemistry results I. A. Representative photomicrographs 
of the 5-HTT expression in the C1-C2 segments from the treatment groups. The expression of 
5-HTT is not equal between the measured laminae. Laminae I and III contain higher density 
of fibres compared to lamina II. B. Changes in area fractions of 5-HTT-immunoreactive fibres 
in superficial laminae I, II and III of the C1-C2 segments. In the NTG and AEA group, the 
area covered by 5-HTT was significantly higher than in the placebo group. NTG+AEA 
treatment abolished this effect. Bars present means ± SEM. ##p<0.01; $$p<0.01; **p<0.01; 
***p<0.001 Scale bar: 100 µm 
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Figure 2. Summary of immunhistochemistry results II.  
A. Representative photomicrographs of the 5-HTT varicose fibres expression in laminae I-III 
of C1-C2 segments from the treatment groups.  
B. Changes in varicosity sizes of 5-HTT in superficial laminae I-III of the C1-C2 segments. In 
the NTG and AEA group, the varicosity size of 5-HTT was significantly higher than in the 
placebo group. NTG+AEA treatment reduced this effect. Figure shows means ± SEM. 
*p<0.05; Scale bar: 100 µm 
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Figure 3. Summary of Western blot data. A. Western blots of 5-HTT and GAPDH expression 
in the C1-C2. B. The quantitative analysis shows that in the NTG and AEA groups, the 
relative optical density of 5-HTT specific bands was significantly higher than in the placebo 
group. NTG+AEA treatment abolished this effect. #p<0.05; $$p<0.01; **p<0.01 
